Update shared on16 Aug 2025
Fair value Increased 37%Despite a moderation in consensus revenue growth forecasts, a higher future P/E multiple has driven the consensus analyst price target for JD Health International up from HK$45.99 to HK$49.62.
What's in the News
- Board meeting scheduled to approve unaudited interim results for the six months ended June 30, 2025.
- Board will consider recommendation for payment of an interim dividend.
Valuation Changes
Summary of Valuation Changes for JD Health International
- The Consensus Analyst Price Target has risen from HK$45.99 to HK$49.62.
- The Consensus Revenue Growth forecasts for JD Health International has fallen from 13.5% per annum to 12.4% per annum.
- The Future P/E for JD Health International has risen from 33.44x to 35.13x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.